In the 1990s, the clinical application of argon helium cryotherapy in prostate cancer was still in the exploratory stage, therefore, the treatment was mainly for patients who had local recurrence after radiotherapy. These patients are mostly early stage patients, but are at high risk of recurrence, i.e., after the prostate-specific antigen (PSA) drops to normal after treatment, it rises again and stays at a certain level for a certain period of time (biochemical recurrence), and the signs of local recurrence of prostate are seen on imaging (ultrasound, MRI) and confirmed by pathological biopsy. Accordingly, the method of local cryotherapy, called salvage therapy, is used. It was affirmed due to satisfactory long-term follow-up results after treatment, and only then gradually transitioned to and became the treatment of choice for prostate cancer. Clinical studies have shown that cryotherapy is not immune to local recurrence, but, unlike other techniques, it can “cut itself with its own knife”. Therefore, in foreign countries, remedial cryotherapy is a very important tool for people who are at risk of recurrence after treatment, although they are at an early stage. In contrast to foreign countries, most of our patients are in the middle to late stage; the treatment before recurrence is complicated; many patients have local recurrence with metastasis, therefore, remedial treatment should also be treated specifically. According to the situation of remedial treatment cases we have completed, most of them are local recurrences after surgical testicular debulking surgery, failure of pharmacological endocrine therapy (hormone refractory or hormone non-dependent), radiotherapy, radioactive particle implantation (brachytherapy), and also a few cryotherapy. If local recurrence is diagnosed, the outcome and prognosis of the selected remedial treatment is ideal. For those who have both local recurrence and metastasis, the issue of local versus systemic treatment is involved, which is more common in China.